Table 2

- Summary of real-life studies supporting the safety and efficacy of anti-VEGFs.

StudyDrugsStudy designPatient statusNumber (eyes)Follow-up (months)Mean number IVIBaseline VA (letters)Final VA (letters)Mean VA gain (letters)Mean CRT reductionIOPCataract progression/extraction
Bahrami et al91AfliberceptProspectiveNon-Naïve436567.8713.237 μm0% (IOP ≥25 mmHg or a rise of IOP ≥10 mmHg)0%
Kaiho et al92AfliberceptNDNon-Naïve51123.865.5704.5NDNDND
Aksoy et al93BevacizumabProspectiveNaïve20665155.54.5210 μm10% (IOP >21 mmHg)2.50%
Fong et al94BevacizumabRetrospectiveMixed (65% naive, 30% laser, 4% steroid)309243.15762.35.3NDNDND
Güler et al95BevacizumabProspectiveND209638424295 ± 42 μmND0%
Koc et al96BevacizumabRetrospectiveNaïve90244.945.248.73.574.7 ± 133.9ND13.70%
Riazi-Esfahani et al97BevacizumabNDNaïve466 67.572.55102 ± 1086.5% (IOP ≥21 mmHg)0
Cheema et al98Bevacizumab (diffuse)RetrospectiveND2861.344451NDNDND
Ciulla et al99RanibizumabRetrospectiveNon-Naïve331265963444 μmNDND
Egan et al100RanibizumabRetrospectiveMixed (49.6% Naive)3103245.451.152.51.4NDNDND

IVI: intravitreal injection, VA: visual acuity, CR: central retnal thickness, IOP: intra-ocular pressure, ND: not determined/detected